Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 2, 1997, Pages 565-572

  Feldman, Daniel J ^a   Frank, Robert A ^a   Kehne, John H ^b   Flannery, Richard ^a   Brown, Danyel ^a   Soni, Shilpa ^a   Byrd, Gen ^a   Shah, Sonali ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b SANOFI   (France)

Author keywords

5 HT2 receptor; Amphetamine; Apomorphine; Atypical neuroleptics; D2 receptor; Extrapyramidal side effects; Haloperidol; MDL 100,907; MDL 28,133A; Rat; Stereotypy

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPHETAMINE; APOMORPHINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; MDL 28133A; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOROBENZENE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY; ANIMAL; ANIMAL BEHAVIOR; DOSE RESPONSE; DRUG EFFECT; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS; STEREOTYPED BEHAVIOR;

EID: 0030609835     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00292-X     Document Type: Article

References (31)

1. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20:1963;140-1441.
2. Chipkin R. E., Iorio L. C., Coffin V. L., McQuade R. D., Berger J. G., Barnett A. Pharmacological profile of SCH39166. a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity J. Pharmacol. Exp. Ther. 247:1988;1093-1102.
3. Creese I., Iverson S. D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res. 83:1975;419-436.
4. Creese I., Burt D. R., Snyder S. Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs. Science. 192:1976;481-483.
5. Creese I., Sibley D. R., Hamblin M. W., Leff S. E. The classification of dopamine receptors Relationship to radioligand binding. Annu. Rev. Neurosci. 6:1983;43-72.
6. Dray A., Davies J., Oakley N. R., Tongroach P., Vellucci S. The dorsal and median projections to the substantia nigra in rat. electrophysiological, biochemical, and behavioral observations Brain Res. 151:1978;431-442.
7. Fibiger H. C., Miller J. J. An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience. 2:1977;975-987.
8. Frank R. A., Tsibulsky V., Grocki S., Dashevsky B, Kehne J. H., Schmidt C. J., Sorensen S. M. Mixed D2/5-HT2A antagonism of amphetamine-induced facilitation of brain stimulation reward. Pharmacol. Biochem. Behav. 52:1995;799-804.
9. Giambalvo C. T., Snodgrass S. R. Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system. Comparison of injection sites Brain Res. 152:1978;555-566.
10. Hiroi N., White N. M. Conditioned stereotypy. Behavioral specification of the UCS and pharmacological investigation of the neural change Pharmacol. Biochem. Behav. 32:1989;249-258.
11. Janssen P. A. J., Niemegeers C. J. C., Jageneau A. H. M. Apomorphine-antagonism in rats. Arnzeimittel-Forschung. 10:1960;1003-1005.
12. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277:1996;968-981.
13. 2A antagonist MDL 100,907 on (±)3,4-methylenedioxymethamphetamine (MDMA) induced locomotor stimulation in rats. Neuropsychopharmacology. 15:1996;116-124.
14. Kelly P. H., Seviour P. W., Iverson S. D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94:1975;507-522.
15. Lacosta S., Roberts D. C. S. MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. Pharmacol. Biochem. Behav. 44:1993;161-165.
16. Lieberman J. A., Kane J. M., Johns C. A. Clozapine. Guidelines for clinical management J. Clin. Psychiatr. 50:1989;329-338.
17. Ljungberg T., Ungerstedt U. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing. evidence for two different mechanisms of action Psychopharmacology. 56:1978;239-247.
18. Mabry P. D., Campbell B. A. Serotonergic inhibition of catecholamine-induced behavioral arousal. Brain Res. 49:1973;381-391.
19. Meltzer H. Y. Atypical antipsychotic drugs. Bloom F. E., Kupfer D. J. Pharmacology. The fourth generation of progress:1995;1277-1286 Raven Press, New York.
20. 2A antagonist. Behav. Brain Res. 73:1995;163-167.
21. Myers J. L., Well A. D. Research design and statistical analysis. 1991;Harper Collins, New York.
22. Nash J. F. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 47:1990;2401.
23. 3 mediated control of dopaminergic function. Psychopharmacology. 112:1993;S60-S67.
24. Robbins T. W., Mittleman G., O'Brien J., Winn P. The neuropsychological significance of stereotypy induced by stimulant drugs. Cooper S. J., Dourish C. T. Neurobiology of stereotyped behavior. 1990;25-63 Oxford University Press, Oxford.
25. Roth B. L., Meltzer H. Y. The role of serotonin in schizophrenia. Bloom F. E., Cooper D. J. Psychopharmacology. The fourth generation of progress:1995;1215-1227 Raven Press, New York.
26. 2 receptors exert a state dependent regulation of dopaminergic function. Studies with MDL 100,907 and the amphetamine analogue, 3, 4-methylenedioxymethamphetamine European Journal of Pharmacology. 223:1992;65-74.
27. Segal D. S. Differential effects of parachlorophenylalanine on amphetamine-induced locomotion and stereotypy. Brain Res. 116:1976;267-276.
28. Segal D. S., Weinstock M. Differential effects of 5-hydroxytryptamine antagonists on behaviors resulting from activation of different pathways arising from the raphe nuclei. Psychopharmacology. 79:1983;72-78.
29. 2 receptor antagonist, MDL 100,907, as a putative atypical antipsychotic. behavioral, electrophysiological, and neurochemical studies J. Pharmacol. Exp. Ther. 266:1993;684-691.
30. 2 modulation of psychostimulant-induced facilitation of brain stimulation reward. Drug Dev. Res. 34:1995;297-305.
31. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology. 98:1989;45-50.